Table 3

 Pros and cons of including C reactive protein (CRP) in future clinical trials in inflammatory bowel disease

In favour of including CRP in clinical trialsAgainst including CRP in clinical trials
(1) Allows objective selection of patients with active disease(1) Carries risk of restricting drugs to patient with high CRP
(2) Higher likelihood of response and lower placebo response rates(2) Risk of more restrictive FDA label
(3) Objective marker for follow up effect of treatment(3) Yet unclear which CRP cut off value is best